370 related articles for article (PubMed ID: 27920180)
1. Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus.
DeZure AD; Berkowitz NM; Graham BS; Ledgerwood JE
J Infect Dis; 2016 Dec; 214(suppl 5):S497-S499. PubMed ID: 27920180
[TBL] [Abstract][Full Text] [Related]
2. Co-Immunization With CHIKV VLP and DNA Vaccines Induces a Promising Humoral Response in Mice.
Zhao Z; Deng Y; Niu P; Song J; Wang W; Du Y; Huang B; Wang W; Zhang L; Zhao P; Tan W
Front Immunol; 2021; 12():655743. PubMed ID: 33868299
[TBL] [Abstract][Full Text] [Related]
3. Chikungunya virus vaccines: Current strategies and prospects for developing plant-made vaccines.
Salazar-González JA; Angulo C; Rosales-Mendoza S
Vaccine; 2015 Jul; 33(31):3650-8. PubMed ID: 26073010
[TBL] [Abstract][Full Text] [Related]
4. A Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes.
Goo L; Dowd KA; Lin TY; Mascola JR; Graham BS; Ledgerwood JE; Pierson TC
J Infect Dis; 2016 Nov; 214(10):1487-1491. PubMed ID: 27655868
[TBL] [Abstract][Full Text] [Related]
5. Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial.
Chen GL; Coates EE; Plummer SH; Carter CA; Berkowitz N; Conan-Cibotti M; Cox JH; Beck A; O'Callahan M; Andrews C; Gordon IJ; Larkin B; Lampley R; Kaltovich F; Gall J; Carlton K; Mendy J; Haney D; May J; Bray A; Bailer RT; Dowd KA; Brockett B; Gordon D; Koup RA; Schwartz R; Mascola JR; Graham BS; Pierson TC; Donastorg Y; Rosario N; Pape JW; Hoen B; Cabié A; Diaz C; Ledgerwood JE;
JAMA; 2020 Apr; 323(14):1369-1377. PubMed ID: 32286643
[TBL] [Abstract][Full Text] [Related]
6. A chikungunya fever vaccine utilizing an insect-specific virus platform.
Erasmus JH; Auguste AJ; Kaelber JT; Luo H; Rossi SL; Fenton K; Leal G; Kim DY; Chiu W; Wang T; Frolov I; Nasar F; Weaver SC
Nat Med; 2017 Feb; 23(2):192-199. PubMed ID: 27991917
[TBL] [Abstract][Full Text] [Related]
7. Development of Vaccines for Chikungunya Fever.
Erasmus JH; Rossi SL; Weaver SC
J Infect Dis; 2016 Dec; 214(suppl 5):S488-S496. PubMed ID: 27920179
[TBL] [Abstract][Full Text] [Related]
8. Do we need a vaccine against chikungunya?
Rezza G
Pathog Glob Health; 2015 Jun; 109(4):170-3. PubMed ID: 25971340
[TBL] [Abstract][Full Text] [Related]
9. Chikungunya Virus Vaccines: Viral Vector-Based Approaches.
Ramsauer K; Tangy F
J Infect Dis; 2016 Dec; 214(suppl 5):S500-S505. PubMed ID: 27920181
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with a chikungunya virus-like particle vaccine exacerbates disease in aged mice.
Arévalo MT; Huang Y; Jones CA; Ross TM
PLoS Negl Trop Dis; 2019 Apr; 13(4):e0007316. PubMed ID: 31026260
[TBL] [Abstract][Full Text] [Related]
11. Recent development in the strategies projected for chikungunya vaccine in humans.
Goyal M; Chauhan A; Goyal V; Jaiswal N; Singh S; Singh M
Drug Des Devel Ther; 2018; 12():4195-4206. PubMed ID: 30573950
[TBL] [Abstract][Full Text] [Related]
12. Regulatory considerations in development of vaccines to prevent disease caused by Chikungunya virus.
Yang S; Fink D; Hulse A; Pratt RD
Vaccine; 2017 Sep; 35(37):4851-4858. PubMed ID: 28760614
[TBL] [Abstract][Full Text] [Related]
13. Chikungunya vaccines in development.
Schwameis M; Buchtele N; Wadowski PP; Schoergenhofer C; Jilma B
Hum Vaccin Immunother; 2016 Mar; 12(3):716-31. PubMed ID: 26554522
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal Antibodies as Prophylactic and Therapeutic Agents Against Chikungunya Virus.
Clayton AM
J Infect Dis; 2016 Dec; 214(suppl 5):S506-S509. PubMed ID: 27920182
[TBL] [Abstract][Full Text] [Related]
15. Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits.
Metz SW; Martina BE; van den Doel P; Geertsema C; Osterhaus AD; Vlak JM; Pijlman GP
Vaccine; 2013 Dec; 31(51):6092-6. PubMed ID: 24099875
[TBL] [Abstract][Full Text] [Related]
16. A patent perspective on chikungunya.
Dapurkar D; Telang M
Acta Trop; 2019 Nov; 199():105131. PubMed ID: 31401192
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus.
Kumar M; Sudeep AB; Arankalle VA
Vaccine; 2012 Sep; 30(43):6142-9. PubMed ID: 22884660
[TBL] [Abstract][Full Text] [Related]
18. Therapeutics and vaccines against chikungunya virus.
Ahola T; Couderc T; Ng LF; Hallengärd D; Powers A; Lecuit M; Esteban M; Merits A; Roques P; Liljeström P
Vector Borne Zoonotic Dis; 2015 Apr; 15(4):250-7. PubMed ID: 25897811
[TBL] [Abstract][Full Text] [Related]
19. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus.
Brandler S; Ruffié C; Combredet C; Brault JB; Najburg V; Prevost MC; Habel A; Tauber E; Desprès P; Tangy F
Vaccine; 2013 Aug; 31(36):3718-25. PubMed ID: 23742993
[TBL] [Abstract][Full Text] [Related]
20. Effective chikungunya virus-like particle vaccine produced in insect cells.
Metz SW; Gardner J; Geertsema C; Le TT; Goh L; Vlak JM; Suhrbier A; Pijlman GP
PLoS Negl Trop Dis; 2013; 7(3):e2124. PubMed ID: 23516657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
